With AbbVie-Allergan decision, Simons draws the line, blasts Dems
Perhaps more than in any other case since Joe Simons became chairman of the Federal Trade Commission, the 3-2 decision approving drugmaker AbbVie’s $63 billion buyout of rival Allergan reveals his...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch